Krystal Biotech (KRYS) Operating Leases (2019 - 2026)

Krystal Biotech has reported Operating Leases for 8 years, with the latest figure at $8.9 million in Q2 2026.

• Operating Leases for Q2 2026 came in at $8.9 million, down 8.55% year-over-year; the trailing twelve-month figure through Jun 2026 was $8.9 million (down 8.55% YoY), and the FY2025 annual result was $7.6 million, up 25.22% from the prior year.
• Operating Leases eased to $8.9 million in Q2 2026, from $9.1 million in the prior quarter.
• Over five years, Operating Leases peaked at $9.7 million in Q2 2025 and troughed at $6.0 million in Q4 2024.
• A 5-year average of $8.5 million and a median of $8.8 million in 2023 frame the typical range for Operating Leases.
• The widest annual swing landed in 2022, when Operating Leases surged 140.16%; it then retreated 25.89% in 2023.
• A 5-year view of Operating Leases shows it stood at $8.9 million in 2022, then dropped by 25.89% to $6.6 million in 2023, then decreased by 8.7% to $6.0 million in 2024, then gained by 25.22% to $7.6 million in 2025, then climbed by 16.98% to $8.9 million in 2026.
• Per Business Quant data, the three most recent Operating Leases figures were $8.9 million in Q2 2026, $9.1 million in Q1 2026, and $7.6 million in Q4 2025.